The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The FDA has awarded 510(k) clearance to Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio in vitro diagnostic (IVD ...

VOV.VN - The Ho Chi Minh City Department of Health has withdrawn 70 registrations for medical devices after uncovering ...

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio enables early detection of amyloid plaques through a non-invasive blood ...

The U.S. Food and Drug Administration (USFDA) has cleared for marketing the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer's disease. The Lumipulse ...

Blake Webb shares trends in automation and microfluidics that are reshaping medical diagnostics and laboratory processes.

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s ...

An Indonesian health official has emphasized the importance of synergy between ASEAN and Japan in strengthening medical ...

The first in vitro diagnostic device that uses blood samples to detect Alzheimer disease has been granted marketing clearance ...

The US Food and Drug Administration today cleared for marketing the first in vitro diagnostic device that tests ...

Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20™ analytical random access platform from EUROIMMUN, ...